San Diego, Calif., February 8, 2021 — NanoCellect Biomedical, Inc. (NanoCellect), and Cytonome/ST, LLC (Cytonome) announced they have agreed to a mutually beneficial settlement agreement to resolve their ongoing patent litigation, without either party admitting any liability.

The settlement ensures the ongoing supply and advancement of NanoCellect’s expanding portfolio of solutions for cell sorting applications utilized by leading life science researchers.  Additionally, the Parties plan to utilize the technical development strengths of both companies to potentially accelerate the development of new solutions in the future.

“We are glad to have this matter resolved and thank the team at Cytonome for their mutually collaborative approach through these negotiations,” said Chris Neary, CEO of NanoCellect.  “This settlement resolution paves the way for our team to accelerate our commercial and technological roadmap and eliminates the ongoing expenses, time, and uncertainty related to addressing this legal matter.”

About NanoCellect:

NanoCellect is a life science tools company manufacturing cell sorters that use proprietary microfluidic technology. NanoCellect’s WOLF Cell Sorter and N1 single cell plate dispenser allow researchers to analyze and separate biological samples one cell at a time. This enables researchers to isolate cells or populations of interest from the rest of the sample. NanoCellect’s WOLF Cell Sorter uses sterile, single-use microfluidic technology. Every part of the fluidics system that touches the sample is disposable, which reduces the risk of cross-contamination between samples. The compact, sturdy, and affordable system can fit almost anywhere, including on a benchtop or in a laminar flow hood.